Podcasts about ons

"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51  "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12

Alleen als de mensensmokkelroutes worden afgesloten zal de ongereguleerde immigratie afnemen. “Daar ziet het onder de nieuwe coalitie niet naar uit”, verzucht Wierd Duk in een nieuwe aflevering van de podcast Het Land van Wierd Duk. “Ons land zal nog verder verdeeld raken”. Verder in de podcast: waarom verzwijgen zoveel media hen onwelgevallige feiten? En: agenten in Utrecht moeten vrezen voor Jihadisten.See omnystudio.com/listener for privacy information.

De broertjes zijn veilig geland in onze studio, glijden PSV en Schouten na midweekse zeperd opnieuw uit, Feyenoord wint wedstrijd maar verliest meer spelers en Youri is Volendam de baas in de ArenA. Verder mag Jeroen Zoet alles met z’n handen pakken, pakt Joel Drommel alles, wint NEC de tweede een-letter-verschil-derby op rij en zit Tim als een soort bloedzuiger vast aan de gast van deze week, om er alle informatie ooit uit te zuigen. Onze gast deze week weet echt alles, Adriaan ter Braack ook wel bekend als Sjamadriaan schuift aan in een nieuwe aflevering van De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes  Complete this evaluation for free NCPD. University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety Episode 209: Updates in Chemo PPE and Safe Handling ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE National Hazardous Drug Exposure Registry Safeguards Oncology Professionals NIOSH Releases Its 2024 List of Hazardous Drugs Safe Handling—We've Come a Long Way, Baby! Strategies to Promote Safe Medication Administration Practices Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads ONS books: Safe Handling of Hazardous Drugs (fourth edition) Safe Handling of Hazardous Drugs Quick Guide™ ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination Oncology Nursing Forum articles: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Other ONS resources: ONS Safe Handling of Hazardous Drugs Quick Guide Introduction to Safe Handling Huddle Card Safe Handling of Hazardous Drugs Learning Library Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We thought that in order to answer some of the unclear questions about health risk, we would set up an exposure registry, in this case, for oncology personnel who handle the drugs. This would then create a cohort that we could ask questions to. For example, we could try to characterize whether there is a cancer excess in this group. Or characterize the reproductive abnormalities in excess that people are experiencing." TS 6:21 "It's sort of counterintuitive that the healthcare industry, whose mission itself is care of the sick, is a high-hazard industry. We typically think about the risk as being from infectious diseases, and certainly we've all lived in our practice lifetime through some examples of that. Even before COVID-19, some of us were doing preparation for Ebola and that sort of thing. So, we're kind of used to that. But the hazards that you kind of grew up with, we've routinized or normalized handling group one, human carcinogens, which a number of these drugs are—it's just something we do every day. Well, it is, but we have to do it with respect and with care every day. And I think sometimes in that routineness of it, we have sort of lost sight of the vigilance that we need to maintain." TS 11:19 "It's very easy in the life cycle of a drug in an organization to do something that doesn't just impact you, but unknowingly, you've contaminated a surface for somebody who comes behind you. Who maybe doesn't have plastic protective equipment on because something that got contaminated shouldn't have been contaminated in the first place. If we could all be thinking of it as more of a team sport, especially in terms of safe handling, that our disposition and drug handling affects not just us and our health, but those of our colleagues." TS 24:47 "For the job history pieces, we ask what year you started, what year you stopped, and we ask about estimations of handling. So we'll be able to come up with either a duration or some kind of metric for the intensity and duration of your handling history, which will then permit us to sort the population who completed the survey into sort of low, medium, high. And we'll see whether the health outcomes that are being reported are influenced by that drug handling history." TS 27:45 "The idea that we aren't exposed to the same therapeutic dose we give to our patients is absolutely true. However, the dosing schedule to them versus us is very different, and we are exposed frequently, if not daily, to very small concentrations. They don't reach a cytotoxic dose necessarily, but we do know from a lot of studies that either ourselves or our colleagues are taking up drug from contaminated work environments. And you've probably seen there is an awful lot of intermediate evidence looking at genotoxic insult in pharmacists and nurses who handle the drugs. So clearly we're showing uptake and we're showing that there are biologically plausible, concerning measures that are taking place in us. So, I think that we need to come back and circle around the idea that we need to have deep respect for the toxicity of these agents." TS 35:03

De broertjes zijn gevlogen, Pepijn gaat los in de après-ski, maar gelukkig zijn Snijboon en Rogier er nog om een aflevering te maken, dat doen ze niet alleen, maar met de gast van deze week: KOERT WESTERMAN✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy ONS Voice articles: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications Cancer Mortality Declines Among Black Patients but Remains Disproportionately High Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Diagnose and Treat Hypercalcemia of Malignancy ONS books: BMTCN® Certification Review Manual (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing articles: African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures Other ONS resources: Financial Toxicity Huddle Card Hypercalcemia of Malignancy Huddle Card Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Cancer Society article: What Is Multiple Myeloma? Blood Cancer United educational resources page International Myeloma Foundation homepage Myeloma University homepage Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked to aging populations. Although, the highest rates are in high-income countries. So, if we look at some of the risk factors, and several have been identified, including MGUS. MGUS is a benign precursor of myeloma, and it stands for monoclonal gammopathy of undetermined significance. Older age is also a risk factor, although we do see patients that are younger who are diagnosed with myeloma." TS 1:54 "Bone pain, specifically in the back, and fatigue, are very common symptoms that relate to things that are going on behind the scenes with myeloma. But also, patients can be bothered by frequent and long-lasting infections. So, they find that they get sick more frequently than their family and friends, and they take a longer time to recover. That could also be a presenting sign. I think there can be some presenting signs and symptoms related to electrolyte abnormalities, especially in later stages. They might be nauseated, vomiting, or constipated. Also, signs and symptoms related to cytopenias. You have to remember that this is a bone marrow cancer. So, we do have some problem with development of normal blood cells. So, we can see not only infections, but bleeding issues related to thrombocytopenia and factors related to anemia from low red blood cell counts." TS 7:15 "About 20%–25% of our patients who are diagnosed are asymptomatic. They have no symptoms. They're living their lives, they're going to work or they're traveling, playing golf on the weekends, taking care of their children or grandchildren. They are just living their lives. And at times, they go to the primary care physician and then they're referred to a hematologist-oncologist, and they're pretty surprised when they're sent to a cancer center. The way they are diagnosed in this matter is that their routine lab work, the complete blood cell count may be normal, there may be some slight differences in their hemoglobin. But what we see in the chemistry, the complete metabolic panel, is an elevation in their total protein and or an elevation of the total globulins." TS 9:22 "The bone marrow biopsy serves many purposes. You want to determine the percentage of bone marrow plasma cells. So, you want to get the degree of plasmacytosis. And then you want to do really specific tests on those plasma cells. So, you want to isolate the malignant plasma cells and determine, via analysis. So, we do the karyotype, chromosomal studies, fluorescence in situ hybridization (FISH) studies, immunohistochemistry studies, and molecular studies. All of these studies are looking for specific genetic changes in the myeloma cells—looking for translocations or deletions. And it's very important to get that information because we can put patients in a category of having standard-risk disease versus high-risk disease. And that can give us a better picture of what this patient's journey with myeloma may look like." TS 13:41 "When I used to work in lymphoma, I spoke with the physicians who were lymphoma specialists, and they said that they foresee a future in having these assays that detect circulating tumor cells actually take the place of imaging studies like restaging positron-emission tomography (PET), computed tomography (CT) scans. So, it's really amazing, these tests that are on the market now and maybe not as widespread as we'd like, but there's a lot of nice assays out there that will become more popular and used more commonplace in the future that I think are going to help identify myeloma more precisely. ... If you think about myeloma, even with measurable residual disease (MRD), MRD for leukemia, for lymphoma, you take a blood sample, you test it for MRD. For myeloma, you need a bone marrow biopsy. You need a bone marrow sample. You can't do MRD on a blood sample for myeloma. Not yet. But if we perfect these assays and we can eventually detect this, then you're looking at a whole new ballgame. You can even perfect your MRD testing as well. So, it's a very exciting time for some of these heme malignancies." TS 28:09

PSV breekt met winterdepressie en arm, Feyenoord gooit het roer om dezelfde kant op en Ajax won bijna ontspannen. Verder verstoord poedersuiker de suiker oomderby, mochten de NAC fans schaatsend naar het voetbal en verrast Jan Streuer met zijn laatste aankoop. We zijn weer ijsvrij, dus deze week is Martijn van Zijtveld te gast in De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

2026 is a big year for Johnny JR as he sets his sights on winning the London Marathon. And with Dave lacing up his cheating shoes to pound the P of London's streets as well, the team have quezzies.Luckily today's episode features a man who is more than capable of answering said quezzies: friend of the show and running guru Ben Parkes. It's his job to help John hack the London Marathon. Godspeed Ben.But fear not, it's not all running chat. Elis has been on the TV, John is (like Meatloaf) out of hell, and there's a cornucopia of call centre celeb stories to read.Keep your ears peeled for some fine Mad Daddery featuring ancient ONS maps, and the team imagine how John would fare on I'm A Celebrity.Reader of this description, send us an email! The address is elisandjohn@bbc.co.uk and the WhatsApp is 07974 293 022.

"Referring patients to audiology early on has shown dramatic reduction in hearing loss or complications because the audiologist can really see where were they at before they started chemotherapy, where were they at during, if they get an audiogram during their treatment. And then after treatment, it's really important for them to see an audiologist because this is really a survivorship journey for them. And as nurses, the 'so what': We are the first line of defense," ONS member Jennessa Rooker, PhD, RN, OCN®, director of nursing excellence at the Tampa General Hospital Cancer Institute in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ototoxicity in cancer care. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 9, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of ototoxicity after chemotherapy treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Cancer Symptom Management Basics series ONS Voice articles: Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Carboplatin Oncology Drug Reference Sheet: Oxaliplatin FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) American Cancer Society resources: 4 Causes of Hearing Problems for Cancer Survivors Cancer Survivors Network American Speech-Language-Hearing Association (ASHA) Hearing Loss: An Under-Recognized Side Effect of Cancer Treatment Embedded Ear Care: Audiology on the Cancer Treatment Team American Society of Clinical Oncology (ASCO) Annual Meeting abstract: Innovative Infusion Center Assessments of Chemotherapy-Induced Neurotoxicities: A Pilot Study Supporting Early and Routine Screenings as Part of Survivorship Programs Children's Oncology Group supportive care endorsed guideline: Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents With Cancer: A Clinical Practice Guideline Ear and Hearing article: Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment International Ototoxicity Management Group (IOMG) IOMG Wikiversity page Shoebox hearing assessments World Health Organization initiative: Make Listening Safe To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "At different pitches, the eardrums move faster or slower, signaling the inner ear, or the cochlea—the thing that looks like a snail in the pictures. The cochlea has fluid and hair cells inside of it that receive movements from the eardrum. The hair cells change the movement into electrical signals that actually go to the auditory nerves or the cranial nerve VIII." TS 2:15 "Ototoxicity is an umbrella term for some sort of exposure to a toxin that causes damage to the inner ear. These toxins can be in the environment, such as loud or different noises, or they can be from medications, including antibiotics or commonly cancer treatments, such as radiation chemotherapy. Some common chemotherapies can be platinum-based chemotherapies like cisplatin or carboplatin. And then what patients are experiencing if they have ototoxicity can be hearing loss." TS 3:15 "The hypothesized mechanism of action is that the chemicals like the platinum compound in cisplatin … that platinum compound travels through our bloodstream. Since chemotherapy is systemic, it'll go to the inner ear, and it gets stuck there by binding to the cellular DNA in that cochlea, or that snail-looking image. That initiates the release of the reactive oxygen species, which are really trying to help clean it out, but releases such high levels that it ends up causing damage to those inner ear hairs. These inner ear hairs cannot regenerate themselves, so then they're permanently damaged. And remember we said that those hairs send electrical signals to the brain that recognize sound. So that function is permanently gone once those hair cells are damaged." TS 7:10 "I definitely think this is a huge interdisciplinary collaborative effort. As nurses and advanced providers, we're assessing and providing education. Our medical oncologists are doing those dose modifications and submitting those audiology referrals. The radiation oncologists are very important to know about this—maybe dose localization awareness. Maybe they do some changes with the doses. And then our audiologists and [ear, nose, and throat physicians], they can do that diagnostic confirmation and any rehabilitation measurements and really monitor them throughout their journey as well. And nurse navigators play a huge part in making sure those patients get those referrals, because a lot of the time the audiologists aren't in the cancer clinic, so they may have to go to another location or may need help coordinating with all their appointments that they have." TS 22:28 "We had a really innovative way of monitoring the hearing that a couple other studies have also tested. It's a remote point-of-care hearing screen. It was on [a tablet] with calibrated headphones. And then it's a paid-for subscription to an audiology testing platform. … Myself, along with a couple of other nurses, were trained how to use this testing device with the tablet and the headphones and the software program. And it was a quick down-and-dirty portable hearing assessment for patients. So anyone who was new to cisplatin, never gotten cisplatin treatment before, was enrolled into the study, and they received a hearing test every time that they came for chemo, and we gave it to them during their hydration." TS 28:59  

Join 4-time Grand Slam Champion Kim Clijsters and tennis reporter Blair Henley as they kick off the 2026 tennis season with an exclusive interview with the legendary Ons Jabeur. In this episode, Ons Jabeur opens up about her pregnancy, her experiences with the PIF maternity program, and her official timeline for a comeback in late 2026. Plus, Kim Clijsters provides a personal update on her Achilles recovery and shares her "tennis eye" analysis on the current state of the tour. Welcome to Love All! We're so happy you're here. If you want to hang out with us behind the scenes and stay close to the heart of the game, follow us on all of our socials: https://www.instagram.com/loveallpodcast/ https://www.tiktok.com/@loveallpodcast https://x.com/loveallpodcast  FAVORITE FOLLOWS: Heidi Barlow: https://www.instagram.com/womenshealthwithheidi/?hl=en Courtney Nguyen: https://bsky.app/profile/fortydeucetwits.bsky.social ⏰TIMESTAMPS: 0:00 Welcome to Love All 3:34 Kim's Health Update: Recovering from a ruptured Achilles 4:47 Bonding with Holger Rune over injury rehab. 5:45 “Henley's Headlines” 6:19 Battle of the Sexes 9:54 Venus Williams' AO Wildcard 12:25 Maria Sakkari's Strong Start 14:13 Bouzas Maneiro beats Coco Gauff 17:49 Hubi Hurkacz beats Alexander Zverev 20:04 Ons Jabeur Joins the Show 21:18 Jabeur Pregnancy Update 23:56 Ons' goal to return to the tour by late 2026/early 2027 28:02 Grand Slam pressure vs. starting a family. 31:09 Why Ons stays late to sign every autograph. 35:45 PIF Maternity Program 38:09 Protected Rankings for a return to the Grand Slams. 39:49 Scouting Aryna Sabalenka 42:21 Scouting Iga Świątek 44:00 Scouting Coco Gauff 46:45 How Ons changed her grip as a junior. 48:16 Souting Mirra Andreeva 49:37 Why Ons doesn't like watching tennis as a fan. 51:23 Sakkari's fitness and backhand improvements. 53:16 Reliving the Semifinal 54:04 Favorite meal 55:19 Alternate Career 56:18 The Best Advice 58:25 Ons' obsession with Harley Davidsons 1:01:19 Favorite Follows Segment 1:03:41 Closing thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

Veerman heeft de boot naar Istanbul gemist, Sem Steijn is gebombardeerd tot ongeveer vierde aanvoerder en Fred Farioli lijkt het tij heel langzaam te keren bij Ajax. Verder is Faber in een ding ter wereld succesvoller dan Thomas Müller, vliegen de Eagles te dicht bij de streep en hebben we te maken met een suikeroomderby. Welkom bij een nieuwe aflevering van De Derde Helft. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for December 28-January 3, 2025: 1. FDA Grants 510(k) Clearance to First Umbilical Cord–Derived Sheet Formulation for Wound Care The FDA granted 510(k) clearance to StimLabs' Theracor, marking the first umbilical cord–derived wound care device available in a sheet formulation. 2. FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion The FDA approved tradipitant as the first new pharmacologic option in decades for preventing motion sickness–related vomiting. 3. FDA Issues Complete Response Letter for Relacorilant for Hypercortisolism The FDA issued a CRL for relacorilant, citing the need for additional evidence of effectiveness despite positive findings from completed trials. 4. FDA Issues Complete Response Letter for ONS-5010 for Wet AMD The FDA again declined approval of ONS-5010 for wet AMD, reiterating that confirmatory evidence of efficacy is required to support the application. 5. FDA Accepts, Grants Priority Review to AXS-05 sNDA for Alzheimer's Disease Agitation The FDA accepted and granted Priority Review to the sNDA for AXS-05, advancing a potential new treatment option for agitation in Alzheimer's disease.

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

De Laatse LessenInleidingOnze laatste lessen zullen zoveel mogelijk vrij van woorden blijven. We gebruiken ze alleen bij het begin van onze oefening, en alleen maar om ons eraan te herinneren dat we ernaar streven daaraan voorbij te gaan. Laten we ons tot Hem wenden die ons voorgaat op de weg en onze schreden zeker maakt. Aan Hem laten we deze lessen over, zoals we voortaan ons leven geven aan Hem. Want we willen niet opnieuw terugkeren naar het geloof in zonde, dat gemaakt heeft dat de wereld lelijk en onveilig leek, aanvallend en vernietigend, gevaarlijk in al haar wegen en zo verraderlijk dat er geen hoop op vertrouwen en ontsnapping aan pijn mogelijk leek.Zijn weg is de enige waarmee we de vrede vinden die God ons gegeven heeft. Het is Zijn weg die ieder in het eind moet gaan, omdat dit het eind is dat God Zelf heeft vastgesteld. In de droom van de tijd lijkt het heel ver weg. Maar in waarheid is het al hier, en dient het ons al als genadige leiding op de weg die we moeten gaan. Laten we samen de weg volgen die de waarheid ons wijst. En laten we de leiders zijn van onze vele broeders die op zoek zijn naar de weg, maar hem niet vinden.En laten we onze denkgeest toewijden aan dit doel, en al onze gedachten erop richten de functie van verlossing te dienen. Ons is het als doel gegeven de wereld te vergeven. Het is het doel dat God ons gegeven heeft. Zijn einde van de droom is wat we zoeken, en niet het onze. Want we zullen niet anders kunnen dan erkennen dat al wat we vergeven, deel uitmaakt van God Zelf. En zo wordt de herinnering van Hem teruggegeven, volledig en compleet.Het is onze functie ons op aarde Hem te herinneren, zoals het ons gegeven is in de werkelijkheid Zijn eigen compleetheid te zijn. Laten we dus niet vergeten dat ons doel gedeeld wordt, want het is die gedachtenis die de Godsherinnering bevat en de weg wijst naar Hem en naar de Hemel van Zijn vrede. Zullen we onze broeder, die ons dit kan bieden, dan niet vergeven? Hij is de weg, de waarheid en het leven dat ons de weg toont. In hem huist de verlossing die ons, door de vergeving die wij hem schonken, geboden wordt.We zullen dit jaar niet beëindigen zonder de gave die onze Vader aan Zijn heilige Zoon heeft beloofd. Wij zijn vergeven nu. En we zijn van alle toorn verlost die we God hadden toegedacht, om te ontdekken dat het een droom was. We hebben onze innerlijke gezondheid hervonden, waarmee we begrijpen dat kwaadheid waanzin is, aanval dwaasheid en wraak niet meer dan een malle fantasie. We zijn van de toorn verlost omdat we begrepen hebben dat we ons hadden vergist. Niets meer dan dat. En is een vader boos op zijn zoon omdat die de waarheid niet begrepen heeft?We komen in alle eerlijkheid tot God en zeggen dat we het niet begrepen hebben, en vragen Hem ons te helpen Zijn lessen te leren, met behulp van de Stem van Zijn eigen Leraar. Zou Hij Zijn Zoon willen kwetsen? Of zou Hij Zich haasten hem te antwoorden en zeggen: ‘Dit is Mijn Zoon, en al wat het Mijne is, is het zijne'? Wees er zeker van dat Hij zo zal antwoorden, want dit zijn Zijn eigen woorden aan jou. En meer dan dat kan niemand ooit hebben, want deze woorden bevatten alles wat er is, en alles wat er in alle tijden en in eeuwigheid zal zijn.LES 365Dit heilig ogenblik wil ik U geven. Neemt U het in handen. Want U wil ik volgen, in de zekerheid dat Uw leiding mij vrede geeft.En als ik een woord nodig heb om me te helpen, zal Hij het me geven. Als ik een gedachte nodig heb, geeft Hij me die ook. En als ik alleen maar stilheid nodig heb en een rustige, open denkgeest, dan zijn dat de gaven die ik van Hem ontvangen zal. Hij heeft de leiding, op mijn verzoek. En Hij zal me horen en antwoord geven, want Hij spreekt namens God, mijn Vader, en Zijn heilige Zoon.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

De Laatse LessenInleidingOnze laatste lessen zullen zoveel mogelijk vrij van woorden blijven. We gebruiken ze alleen bij het begin van onze oefening, en alleen maar om ons eraan te herinneren dat we ernaar streven daaraan voorbij te gaan. Laten we ons tot Hem wenden die ons voorgaat op de weg en onze schreden zeker maakt. Aan Hem laten we deze lessen over, zoals we voortaan ons leven geven aan Hem. Want we willen niet opnieuw terugkeren naar het geloof in zonde, dat gemaakt heeft dat de wereld lelijk en onveilig leek, aanvallend en vernietigend, gevaarlijk in al haar wegen en zo verraderlijk dat er geen hoop op vertrouwen en ontsnapping aan pijn mogelijk leek.Zijn weg is de enige waarmee we de vrede vinden die God ons gegeven heeft. Het is Zijn weg die ieder in het eind moet gaan, omdat dit het eind is dat God Zelf heeft vastgesteld. In de droom van de tijd lijkt het heel ver weg. Maar in waarheid is het al hier, en dient het ons al als genadige leiding op de weg die we moeten gaan. Laten we samen de weg volgen die de waarheid ons wijst. En laten we de leiders zijn van onze vele broeders die op zoek zijn naar de weg, maar hem niet vinden.En laten we onze denkgeest toewijden aan dit doel, en al onze gedachten erop richten de functie van verlossing te dienen. Ons is het als doel gegeven de wereld te vergeven. Het is het doel dat God ons gegeven heeft. Zijn einde van de droom is wat we zoeken, en niet het onze. Want we zullen niet anders kunnen dan erkennen dat al wat we vergeven, deel uitmaakt van God Zelf. En zo wordt de herinnering van Hem teruggegeven, volledig en compleet.Het is onze functie ons op aarde Hem te herinneren, zoals het ons gegeven is in de werkelijkheid Zijn eigen compleetheid te zijn. Laten we dus niet vergeten dat ons doel gedeeld wordt, want het is die gedachtenis die de Godsherinnering bevat en de weg wijst naar Hem en naar de Hemel van Zijn vrede. Zullen we onze broeder, die ons dit kan bieden, dan niet vergeven? Hij is de weg, de waarheid en het leven dat ons de weg toont. In hem huist de verlossing die ons, door de vergeving die wij hem schonken, geboden wordt.We zullen dit jaar niet beëindigen zonder de gave die onze Vader aan Zijn heilige Zoon heeft beloofd. Wij zijn vergeven nu. En we zijn van alle toorn verlost die we God hadden toegedacht, om te ontdekken dat het een droom was. We hebben onze innerlijke gezondheid hervonden, waarmee we begrijpen dat kwaadheid waanzin is, aanval dwaasheid en wraak niet meer dan een malle fantasie. We zijn van de toorn verlost omdat we begrepen hebben dat we ons hadden vergist. Niets meer dan dat. En is een vader boos op zijn zoon omdat die de waarheid niet begrepen heeft?We komen in alle eerlijkheid tot God en zeggen dat we het niet begrepen hebben, en vragen Hem ons te helpen Zijn lessen te leren, met behulp van de Stem van Zijn eigen Leraar. Zou Hij Zijn Zoon willen kwetsen? Of zou Hij Zich haasten hem te antwoorden en zeggen: ‘Dit is Mijn Zoon, en al wat het Mijne is, is het zijne'? Wees er zeker van dat Hij zo zal antwoorden, want dit zijn Zijn eigen woorden aan jou. En meer dan dat kan niemand ooit hebben, want deze woorden bevatten alles wat er is, en alles wat er in alle tijden en in eeuwigheid zal zijn.LES 364Dit heilig ogenblik wil ik U geven. Neemt U het in handen. Want U wil ik volgen, in de zekerheid dat Uw leiding mij vrede geeft.En als ik een woord nodig heb om me te helpen, zal Hij het me geven. Als ik een gedachte nodig heb, geeft Hij me die ook. En als ik alleen maar stilheid nodig heb en een rustige, open denkgeest, dan zijn dat de gaven die ik van Hem ontvangen zal. Hij heeft de leiding, op mijn verzoek. En Hij zal me horen en antwoord geven, want Hij spreekt namens God, mijn Vader, en Zijn heilige Zoon.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

De Laatse LessenInleidingOnze laatste lessen zullen zoveel mogelijk vrij van woorden blijven. We gebruiken ze alleen bij het begin van onze oefening, en alleen maar om ons eraan te herinneren dat we ernaar streven daaraan voorbij te gaan. Laten we ons tot Hem wenden die ons voorgaat op de weg en onze schreden zeker maakt. Aan Hem laten we deze lessen over, zoals we voortaan ons leven geven aan Hem. Want we willen niet opnieuw terugkeren naar het geloof in zonde, dat gemaakt heeft dat de wereld lelijk en onveilig leek, aanvallend en vernietigend, gevaarlijk in al haar wegen en zo verraderlijk dat er geen hoop op vertrouwen en ontsnapping aan pijn mogelijk leek.Zijn weg is de enige waarmee we de vrede vinden die God ons gegeven heeft. Het is Zijn weg die ieder in het eind moet gaan, omdat dit het eind is dat God Zelf heeft vastgesteld. In de droom van de tijd lijkt het heel ver weg. Maar in waarheid is het al hier, en dient het ons al als genadige leiding op de weg die we moeten gaan. Laten we samen de weg volgen die de waarheid ons wijst. En laten we de leiders zijn van onze vele broeders die op zoek zijn naar de weg, maar hem niet vinden.En laten we onze denkgeest toewijden aan dit doel, en al onze gedachten erop richten de functie van verlossing te dienen. Ons is het als doel gegeven de wereld te vergeven. Het is het doel dat God ons gegeven heeft. Zijn einde van de droom is wat we zoeken, en niet het onze. Want we zullen niet anders kunnen dan erkennen dat al wat we vergeven, deel uitmaakt van God Zelf. En zo wordt de herinnering van Hem teruggegeven, volledig en compleet.Het is onze functie ons op aarde Hem te herinneren, zoals het ons gegeven is in de werkelijkheid Zijn eigen compleetheid te zijn. Laten we dus niet vergeten dat ons doel gedeeld wordt, want het is die gedachtenis die de Godsherinnering bevat en de weg wijst naar Hem en naar de Hemel van Zijn vrede. Zullen we onze broeder, die ons dit kan bieden, dan niet vergeven? Hij is de weg, de waarheid en het leven dat ons de weg toont. In hem huist de verlossing die ons, door de vergeving die wij hem schonken, geboden wordt.We zullen dit jaar niet beëindigen zonder de gave die onze Vader aan Zijn heilige Zoon heeft beloofd. Wij zijn vergeven nu. En we zijn van alle toorn verlost die we God hadden toegedacht, om te ontdekken dat het een droom was. We hebben onze innerlijke gezondheid hervonden, waarmee we begrijpen dat kwaadheid waanzin is, aanval dwaasheid en wraak niet meer dan een malle fantasie. We zijn van de toorn verlost omdat we begrepen hebben dat we ons hadden vergist. Niets meer dan dat. En is een vader boos op zijn zoon omdat die de waarheid niet begrepen heeft?We komen in alle eerlijkheid tot God en zeggen dat we het niet begrepen hebben, en vragen Hem ons te helpen Zijn lessen te leren, met behulp van de Stem van Zijn eigen Leraar. Zou Hij Zijn Zoon willen kwetsen? Of zou Hij Zich haasten hem te antwoorden en zeggen: ‘Dit is Mijn Zoon, en al wat het Mijne is, is het zijne'? Wees er zeker van dat Hij zo zal antwoorden, want dit zijn Zijn eigen woorden aan jou. En meer dan dat kan niemand ooit hebben, want deze woorden bevatten alles wat er is, en alles wat er in alle tijden en in eeuwigheid zal zijn.LES 363Dit heilig ogenblik wil ik U geven. Neemt U het in handen. Want U wil ik volgen, in de zekerheid dat Uw leiding mij vrede geeft.En als ik een woord nodig heb om me te helpen, zal Hij het me geven. Als ik een gedachte nodig heb, geeft Hij me die ook. En als ik alleen maar stilheid nodig heb en een rustige, open denkgeest, dan zijn dat de gaven die ik van Hem ontvangen zal. Hij heeft de leiding, op mijn verzoek. En Hij zal me horen en antwoord geven, want Hij spreekt namens God, mijn Vader, en Zijn heilige Zoon.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

De Laatse LessenInleidingOnze laatste lessen zullen zoveel mogelijk vrij van woorden blijven. We gebruiken ze alleen bij het begin van onze oefening, en alleen maar om ons eraan te herinneren dat we ernaar streven daaraan voorbij te gaan. Laten we ons tot Hem wenden die ons voorgaat op de weg en onze schreden zeker maakt. Aan Hem laten we deze lessen over, zoals we voortaan ons leven geven aan Hem. Want we willen niet opnieuw terugkeren naar het geloof in zonde, dat gemaakt heeft dat de wereld lelijk en onveilig leek, aanvallend en vernietigend, gevaarlijk in al haar wegen en zo verraderlijk dat er geen hoop op vertrouwen en ontsnapping aan pijn mogelijk leek.Zijn weg is de enige waarmee we de vrede vinden die God ons gegeven heeft. Het is Zijn weg die ieder in het eind moet gaan, omdat dit het eind is dat God Zelf heeft vastgesteld. In de droom van de tijd lijkt het heel ver weg. Maar in waarheid is het al hier, en dient het ons al als genadige leiding op de weg die we moeten gaan. Laten we samen de weg volgen die de waarheid ons wijst. En laten we de leiders zijn van onze vele broeders die op zoek zijn naar de weg, maar hem niet vinden.En laten we onze denkgeest toewijden aan dit doel, en al onze gedachten erop richten de functie van verlossing te dienen. Ons is het als doel gegeven de wereld te vergeven. Het is het doel dat God ons gegeven heeft. Zijn einde van de droom is wat we zoeken, en niet het onze. Want we zullen niet anders kunnen dan erkennen dat al wat we vergeven, deel uitmaakt van God Zelf. En zo wordt de herinnering van Hem teruggegeven, volledig en compleet.Het is onze functie ons op aarde Hem te herinneren, zoals het ons gegeven is in de werkelijkheid Zijn eigen compleetheid te zijn. Laten we dus niet vergeten dat ons doel gedeeld wordt, want het is die gedachtenis die de Godsherinnering bevat en de weg wijst naar Hem en naar de Hemel van Zijn vrede. Zullen we onze broeder, die ons dit kan bieden, dan niet vergeven? Hij is de weg, de waarheid en het leven dat ons de weg toont. In hem huist de verlossing die ons, door de vergeving die wij hem schonken, geboden wordt.We zullen dit jaar niet beëindigen zonder de gave die onze Vader aan Zijn heilige Zoon heeft beloofd. Wij zijn vergeven nu. En we zijn van alle toorn verlost die we God hadden toegedacht, om te ontdekken dat het een droom was. We hebben onze innerlijke gezondheid hervonden, waarmee we begrijpen dat kwaadheid waanzin is, aanval dwaasheid en wraak niet meer dan een malle fantasie. We zijn van de toorn verlost omdat we begrepen hebben dat we ons hadden vergist. Niets meer dan dat. En is een vader boos op zijn zoon omdat die de waarheid niet begrepen heeft?We komen in alle eerlijkheid tot God en zeggen dat we het niet begrepen hebben, en vragen Hem ons te helpen Zijn lessen te leren, met behulp van de Stem van Zijn eigen Leraar. Zou Hij Zijn Zoon willen kwetsen? Of zou Hij Zich haasten hem te antwoorden en zeggen: ‘Dit is Mijn Zoon, en al wat het Mijne is, is het zijne'? Wees er zeker van dat Hij zo zal antwoorden, want dit zijn Zijn eigen woorden aan jou. En meer dan dat kan niemand ooit hebben, want deze woorden bevatten alles wat er is, en alles wat er in alle tijden en in eeuwigheid zal zijn.LES 362Dit heilig ogenblik wil ik U geven. Neemt U het in handen. Want U wil ik volgen, in de zekerheid dat Uw leiding mij vrede geeft.En als ik een woord nodig heb om me te helpen, zal Hij het me geven. Als ik een gedachte nodig heb, geeft Hij me die ook. En als ik alleen maar stilheid nodig heb en een rustige, open denkgeest, dan zijn dat de gaven die ik van Hem ontvangen zal. Hij heeft de leiding, op mijn verzoek. En Hij zal me horen en antwoord geven, want Hij spreekt namens God, mijn Vader, en Zijn heilige Zoon.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

De Laatse LessenInleidingOnze laatste lessen zullen zoveel mogelijk vrij van woorden blijven. We gebruiken ze alleen bij het begin van onze oefening, en alleen maar om ons eraan te herinneren dat we ernaar streven daaraan voorbij te gaan. Laten we ons tot Hem wenden die ons voorgaat op de weg en onze schreden zeker maakt. Aan Hem laten we deze lessen over, zoals we voortaan ons leven geven aan Hem. Want we willen niet opnieuw terugkeren naar het geloof in zonde, dat gemaakt heeft dat de wereld lelijk en onveilig leek, aanvallend en vernietigend, gevaarlijk in al haar wegen en zo verraderlijk dat er geen hoop op vertrouwen en ontsnapping aan pijn mogelijk leek.Zijn weg is de enige waarmee we de vrede vinden die God ons gegeven heeft. Het is Zijn weg die ieder in het eind moet gaan, omdat dit het eind is dat God Zelf heeft vastgesteld. In de droom van de tijd lijkt het heel ver weg. Maar in waarheid is het al hier, en dient het ons al als genadige leiding op de weg die we moeten gaan. Laten we samen de weg volgen die de waarheid ons wijst. En laten we de leiders zijn van onze vele broeders die op zoek zijn naar de weg, maar hem niet vinden.En laten we onze denkgeest toewijden aan dit doel, en al onze gedachten erop richten de functie van verlossing te dienen. Ons is het als doel gegeven de wereld te vergeven. Het is het doel dat God ons gegeven heeft. Zijn einde van de droom is wat we zoeken, en niet het onze. Want we zullen niet anders kunnen dan erkennen dat al wat we vergeven, deel uitmaakt van God Zelf. En zo wordt de herinnering van Hem teruggegeven, volledig en compleet.Het is onze functie ons op aarde Hem te herinneren, zoals het ons gegeven is in de werkelijkheid Zijn eigen compleetheid te zijn. Laten we dus niet vergeten dat ons doel gedeeld wordt, want het is die gedachtenis die de Godsherinnering bevat en de weg wijst naar Hem en naar de Hemel van Zijn vrede. Zullen we onze broeder, die ons dit kan bieden, dan niet vergeven? Hij is de weg, de waarheid en het leven dat ons de weg toont. In hem huist de verlossing die ons, door de vergeving die wij hem schonken, geboden wordt.We zullen dit jaar niet beëindigen zonder de gave die onze Vader aan Zijn heilige Zoon heeft beloofd. Wij zijn vergeven nu. En we zijn van alle toorn verlost die we God hadden toegedacht, om te ontdekken dat het een droom was. We hebben onze innerlijke gezondheid hervonden, waarmee we begrijpen dat kwaadheid waanzin is, aanval dwaasheid en wraak niet meer dan een malle fantasie. We zijn van de toorn verlost omdat we begrepen hebben dat we ons hadden vergist. Niets meer dan dat. En is een vader boos op zijn zoon omdat die de waarheid niet begrepen heeft?We komen in alle eerlijkheid tot God en zeggen dat we het niet begrepen hebben, en vragen Hem ons te helpen Zijn lessen te leren, met behulp van de Stem van Zijn eigen Leraar. Zou Hij Zijn Zoon willen kwetsen? Of zou Hij Zich haasten hem te antwoorden en zeggen: ‘Dit is Mijn Zoon, en al wat het Mijne is, is het zijne'? Wees er zeker van dat Hij zo zal antwoorden, want dit zijn Zijn eigen woorden aan jou. En meer dan dat kan niemand ooit hebben, want deze woorden bevatten alles wat er is, en alles wat er in alle tijden en in eeuwigheid zal zijn.LES 361Dit heilig ogenblik wil ik U geven. Neemt U het in handen. Want U wil ik volgen, in de zekerheid dat Uw leiding mij vrede geeft.En als ik een woord nodig heb om me te helpen, zal Hij het me geven. Als ik een gedachte nodig heb, geeft Hij me die ook. En als ik alleen maar stilheid nodig heb en een rustige, open denkgeest, dan zijn dat de gaven die ik van Hem ontvangen zal. Hij heeft de leiding, op mijn verzoek. En Hij zal me horen en antwoord geven, want Hij spreekt namens God, mijn Vader, en Zijn heilige Zoon.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

Gautengse gesondheidsowerhede is bekommerd oor die getal tiener-ma's in die provinsie. Die feesseisoen is 'n bitter herinnering van verlies vir slagoffers van bendegeweld in die Wes-Kaap. Verkeersvolumes begin van vandag af weer toeneem. Ons praat met die onderskeie verkeersowerhede.

Die nuusstorie wat vanjaar meer as enige ander op ons sosiale media-platforms afgelaai is, is die storie van die wegraping: die dag toe die musikant en prediker, Danie Botha, aan die wêreld verkondig het dat hy 'n boodskap ontvang het dat die wêreld teen 24 September 2025 sou vergaan. Ons hoor of Botha weer die Woord op dié manier sal verkondig. Ons bring ook vir jou stories oor spesiale kerstradisies vanoor regoor die wêreld en uit Suid-Afrika, spesiale kersdisse, wat mense se kersherinneringe is, hoekom kersfilms soveel heimweë uitlok, en wat die kleingoed in hulle kerskouse wil hê.

Prijzenpakker Bosz breekt nieuw record, John van den Brom vond Feyenoord - FC Twente geen topwedstrijd en 90 minuten Tetris in Nijmegen levert geen winnaar op. Verder lijkt Heracles veel geld te verdienen aan Jizz, gooit Sierhuis weer eens een dubbel en draagt NAC de komende weken de gloeiend hete rode lantaarn. Op naar een nieuwe aflevering van De Derde Helft, deze week met YUKI KEMPEES!✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ons rädstiel

Sigrid Bousset (1969) is cultuurmanager en schrijver. Ze heeft gewerkt voor het Kaaitheater, voor Behoud De Begeerte, ze heeft het internationaal literatuurhuis Passa Porta in Brussel opgericht en geleid. Ze is de dochter van literatuurkenner Hugo Bousset en de vrouw van schrijver Stefan Hertmans die eerder mijn gast was in deze podcast. Ze heeft een boek geschreven over de Vlaamse schrijver Ivo Michiels, die ze al kende in haar kindertijd: Wat ik haar niet vertelde.Ik zocht haar op in Dworp, deelgemeente van Beersel in Vlaams-Brabant, waar het schrijverskoppel woont in een huis met overal boekenkasten en stapels boeken. We gingen boven zitten, in de werkkamer die ze speciaal inrichtte om aan haar boek te werken. Ze vertelt over haar ontmoeting met de Israëlische schrijver David Grossman, over het bierkaartje dat ze heeft met een tekening van Louis Paul Boon. Ons gesprek gaat over jezelf op het spel zetten in boeken, over sterke vrouwen, over de mate waarin haar Ivo-Michielsboek over zichzelf gaat. En ik vraag of zij en haar man gemeenschappelijke boekenkasten hebben, en of ze elkaar feedback geven op hun teksten.Wil je het boek '103 boeken die je gelezen moet hebben' bestellen - het boek van de podcast? Dat kan op ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.be.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ik schrijf er met plezier iets in voor jou of voor de persoon aan wie je het boek cadeau wil doen.Alle boeken en auteurs uit deze aflevering vind je⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠in de shownotes op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de nieuwsbrief in je mailbox? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.substack.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de podcast steunen? Bestel je boeken dan steeds via⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠de ⁠⁠link op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!⁠⁠ Merci.De drie boeken van Sigrid Bousset zijn:1. ⁠⁠⁠⁠⁠⁠⁠David Grossman: Een vrouw op de vlucht voor een bericht2. Ivo Michiels: Het afscheid3. Judith Hermann: KiezelsLuister ook naar de drie boeken van: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stefan Hertmans⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Eva Mouton⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Nicci French⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Josse De Pauw⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ish Ait Hamou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Murielle Scherre⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Michèle Cuvelier⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Françoise Chombar⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠en ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠vele anderen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

REVIEW OF THE YEAR 2025 - Economy & AI   Final part of our 4 part series on the Review of the Year. The two dominant mega themes of this year has undoubtedly been the global economy and the rise of AI. The two are becoming intertwined, especially with the AI investment boom drawing down investments from other parts of the US economy, whilst Trump Trade War 2.0 hobbles global economic growth, likely inadvertently accelerating the adoption of AI...   - Global economic growth 2025 - Jobs Growth / Loss - Sectoral growth / decline - Staffing agency figures - ONS data on unemployed / underemployed - Employment Rights Bill - Immigration - UK vs Europe - UK vs US - UK vs Global Mean - Contact / FTE - Wage growth / decline - Entry level hiring - AI Economy - Adoption patterns and impact on employment - Sectors most exposed, greatest risk / greatest opportunity? - Forecast for 2026 - UK, Europe, US, Globe - Recommendations for TA, Staffing Agencies, Hiring Managers   All this and more on brainfood live on air.   We're with Neil Carberry, MD (Recruitment & Employment Confederation), Belinda Johnson, Founder, (Worklab) & Rt Hon Chloe Smith on Friday 19th December, 2pm GMT.   Register by click on the green button (save my spot) and follow the channel here (recommended) to be noticed when we go live.     Ep349 is sponsored by Recruiting Brainfood   Thank you all for your support in 2025. We cannot do these conversations without the support of our amazing sponsors, our fantastic panelists but most of all, you the viewing public. Thank you and see you next year!

Die Minister van Openbare Werke en Infrastruktuur wil nalatigheid in die konstruksiebedryf strafregtelik vervolg ná die ineenstorting van ‘n Hindoe-tempel by Verulam. Ons ontleed die Wes-Kaap se jongste misdaadsyfers. Teenstrydige berigte oor wat tydens 'n klopjag by 'n Amerikaanse vlugtelingsentrum in Johannesburg gebeur het.

Wat 'n voorreg om terug te kyk op 2025!   Die jaar het so baie op gelewer en so vinnig verby gevlieg, maar die Scriptura span het reekse en episodes gepubliseer wat ons eie verbeelding oortref het.   AAN GOD AL DIE EER, want in werklikheid was dit episode vir episode, 'n groot genade.  En alles het uitgewerk soos dit moes, en ons is baie dankbaar dat die ses broers in die Here al vir 'n volle agt jaar elke week saam gesels oor die Woord van ons wonderlike God. Die bediening bereik duisende mense regoor die wereld, want God het dit so laat gebeur.  Hy gebruik nederige mense om Sy evangelie van redding wêreldwyd te versprei.   En dit het 'n baie positiewe impak op die predikers en aanbieders self, en op die luisteraars, asook op die werkers in die agtergrond meegebring.  Ons bedank elkeen wat geluister en gekyk het, en die episodes met vriende en familie gedeel het, want dit is ook natuurlik die uitvloeisel van die aanraking van die Woord van God in elke hart.   Die liefde van God is soos 'n vuur en dit steek harte aan die brand, en ons kan dit nie vir onsself hou nie. Bid asseblief vir die volgehoue en getroue verkondiging van die Here se kosbare woord, en vir die bediening om voort te gaan om nog meer mense te bereik vir God se koninkryk.

PSV moet winterbanden voor de platte kar bestellen, Van Persie vindt deze Klassieker geen topwedstrijd, en het lijkt of Grimsalabim kan toveren. Verder was AZ dit weekend met Herrie en Berrie op wereldreis, miste Heerenveen deze week drie Luuk Brouwers en bestormt El Karouani de Narsingh-index. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Er worden alsmaar minder baby’s geboren in Europa, ook in ons land. Volgens sommigen eigenlijk angstwekkend weinig. We zijn ook niet de enigen. Van Italië over Rusland tot in China: overal stevenen we af op een razendsnelle bevolkingsafname. Een demografische crisis, vrezen bepaalde experts. Hoe komt het dat we niet genoeg kinderen meer willen maken? Hoe ontwrichtend kan die steile bevolkingsafname worden? En wat kunnen we daar eventueel aan doen? In deze Extra-aflevering van De 7 praten host Roan Van Eyck en journaliste Stephanie De Smedt met experts, burgemeesters en leden van de zes generaties die op dit moment in leven zijn. Over wat een kind vandaag exact kost, hoeveel geld ouders méér bijdragen aan de welvaartsstaat dan niet-ouders, en wat de dalende geboortecijfers nog betekenen voor onze economie. Lees: Wat de politiek ook probeert, ze zet er ons niet toe aan meer baby’s te maken Ons hele Gen6-dossier See omnystudio.com/listener for privacy information.

Ons volledige podcastaanbod vind je in Luister, in de app van De Standaard. Maar je kan als abonnee nu ook onze exclusieve reeksen, zoals Wat nu, Israël?, beluisteren op Spotify. Bij de afleveringen zie je een slotje staan. Als abonnee krijg je toegang door je abonnement op De Standaard (of een andere Mediahuistitel) te koppelen aan je Spotify-account. Klik op het slotje en volg de aangegeven stappen. Enkele kliks verder kan je al luisteren, ook als je geen betalend abonnement hebt bij Spotify. Wil je luisteren en ben je nog geen abonnee? Jongeren onder de 26 trakteren we nog tot eind dit jaar op een abonnement. Ben je ouder dan 26, dan lees én luister je al vanaf 3,15 euro per week. Ga daarvoor naar standaard.be/abonnement.See omnystudio.com/listener for privacy information.

PSV schaatst langs Heerenveen, Ueda scoort een head-trick en Ajax blijft maar winnen in 2026. Verder verliest AZ niet alleen punten maar ook een mascotte, pakt een niet gediplomeerde trainer een trainersprijs en staat Utrecht altijd waar het hoort als Vincent bij ons langskomt. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

Waar zal Europa het geld halen om Oekraïne in 2026 en 2027 structureel te helpen? Als het van 26 lidstaten afhangt: in België, waar minstens 140 miljard euro aan Russische tegoeden geblokkeerd zit. Ideaal voor een “herstellening” aan het getroffen land, meent de EU. Maar premier Bart De Wever houdt het been stijf. Want voor ons land zijn er té veel risico's aan verbonden, meent De Wever. Hij wil het geld pas vrijgeven als er waterdichte garanties komen. Met de Europese top van 18 december in zicht, moet de zaak nu echt wel landen. De politieke en geopolitieke druk op premier Bart De Wever (N-VA) is groot. Ons land staat alleen in zijn verzet tegen het “herstelplan” van de Europese commissievoorzitter Ursula von der Leyen. Komt De Wever hier als winnaar uit? Alles hangt af van de garanties die zullen worden beklonken, en van het akkoord van de 26 andere lidstaten, weet Europawatcher Bart Beirlant van onze buitenlandredactie. CREDITS Journalist Bart Beirlant | Presentatie en eindredactie Marjan Justaert | Redactie Alexander Lippeveld, Sofie Steenhaut | Audioproductie en muziek Brecht Plasschaert | Chef podcast Alexander Lippeveld See omnystudio.com/listener for privacy information.

UnHerd's Freddie Sayers speaks with migration expert Dr. Madeleine Sumption to dissect the latest ONS figures which reveal a dramatic crash in UK net migration. Is this truly caused by an alarming "exodus of fed-up Brits," as some headlines suggest, or is the surge in people leaving the country, in fact, the long-overdue re-migration of earlier non-EU and EU immigrants—a data-driven truth that fundamentally upends how the media and public understand the entire politics of immigration? Hosted on Acast. See acast.com/privacy for more information.

PSV wint de Veerman-derby, Robin van Persie heeft 25 zoons en Ajax blijft ongeslagen door buiten het veld te verliezen. Verder probeerde Troy Ihattaren na-te-papegaaien, trekken de Eagles deze keer een sportieve lange neus en blijft Krüzen als enige Heracles-trainer ooit ongeslagen. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft, deze week met SJOERD MOSSOU! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ons is vandag op die sewende dag van die 16 Dae van Aktivisme teen vrouegeweld. Intussen is twee vroue vermoor, twee verkrag en een kind verwaarloos. Kosmos 94.1 Nuus het met maatskaplike aktivis en direkteur van Civic +264, Ethne Mudge, gepraat. Sy meen dit is van kritieke belang om seuns en mans by die veldtog te betrek.

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Healing is an important piece of rehabilitating trauma. Without healing it can be hard for people to move forward with life and on to healthier behaviors. Today we talk with Dr. Darlene Fry from the IGF Black Youth Healing Arts Center and discover the many different components of healing through the arts.  Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Eindhovense storm zwakt af tot briesje, Feyenoord’s crisismeter begint uit te slaan en de crisismeter van Ajax is volledig opgeblazen. Verder trekt de schokeffect Guardiola de lijn door, hebben we te maken met de oudste-jongste debutant ooit en vieren we de terugkeer van de oranje bal in de Groen-Witte Kathedraal. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukIn this bonus episode, I spoke with Ed West about the new data indicating that British citizens are emigrating in much larger numbers than anyone realised. We also spoke about how emigration has shaped the Anglosphere and the proposed reforms to the asylum system. Discussed in the episode:* ONS revised emigration estimates – https://www.ons.gov.uk/peoplep…

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Morse code transcription: vvv vvv HP seeking 1.7bn from Mike Lynchs estate UK net migration dropped more than first reported, ONS says Sisters jealous ex lit fatal Bradford house fire, jury told How to stop your phone habit ruining your relationship Loose wire on ship may have led to Baltimore bridge collapse, report says Things happen Trump defends Saudi crown prince over Khashoggi killing Strictly Come Dancing La Voix devastated to miss Blackpool specials due to injury Palestine Action activist struck officer with sledgehammer, court hears Snow and ice warnings come into force across Scotland Line of Duty to return for seventh series, BBC confirms

Economics editor Michael Simmons and Yvette Cooper's former adviser Danny Shaw join Patrick Gibbons to react to the Home Secretary's plans for asylum reform. Shabana Mahmood's direct communication style in the Commons yesterday has been praised by government loyalists and right-wingers alike, but her plans have been criticised by figures on the left as apeing Reform. Will her calculated risk pay off and how will success be judged?Plus, as ONS migration figures are revised – again – Michael restates his appeal for more reliable data. And how could migration data affect the budget next week?Produced by Patrick Gibbons.Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcasts.Contact us: podcast@spectator.co.uk Hosted on Acast. See acast.com/privacy for more information.

Het Nederlands Elftal heeft zich, als je dit luistert, hopelijk geplaatst voor het WK, maar vanaf de roze wolk is de opvolging van Koeman nú al onderwerp van gesprek. Verder hoop iedereen op het (als we Dick een beetje inschatten) toch een-na-laatste kunstje van Advocaat en is Halfgod Troy Parrott is minstens tien keer zo goed als Mexx Meerdink. Welkom bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast hebben Snijboon, Tim en Pepijn het over alle zin en onzin rondom het interlandweekend.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

In The People vs. the Golden State Killer, Thien Ho, the current District Attorney of Sacramento, recounts his harrowing and exhilarating experience as the lead prosecutor responsible for capturing and prosecuting Joseph DeAngelo. Referred to at various times by law enforcement and the media as the Visalia Ransacker, the East Bay Rapist, the Original Nightstalker, and finally the Golden State Killer, DeAngelo, a former policeman, is widely considered “one of the most notorious serial predators in American history.Ho's book is the first official account of how the Golden State Killer was apprehended and put behind bars for life. Ho led an elite team of law enforcement from six California prosecutor's offices, using a newly developed tool known as “investigative genetic genealogy” to connect DeAngelo to multiple cold cases stretching back nearly a half century.Many previous narratives about DeAngelo, including two bestselling books and multiple documentaries, focused largely on the killer and his heinous crimes. This book not only provides hundreds of facts and details never revealed to the public about the Golden State Killer's crimes, it also presents the real-life story of the people who worked tirelessly to bring DeAngelo to justice. It also offers the unprecedented authorized perspective of three survivors of DeAngelo's crimes who courageously turned their pain into empowerment and activism. A portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor.The People vs. the Golden State Killer also recounts Ho's fascinating personal journey, from escaping communist Vietnam with his family as a child to working his way up from an internship to an elite homicide division and eventually becoming one of only ten Asian American district attorneys out of 2,400 nationwide. THE PEOPLE vs THE GOLDEN STATE KILLER: Sacramento District Attorney—Thien Ho

"I think we really need to push more of our oncology nurses to get into elected and appointed positions. So often we're looking at health positions to get involved in, and those are wonderful. We need nurses as secretaries of health, but there are others. We as nurses understand higher education. We understand environment. We understand energy. So I think we look broadly at, what are positions we can get in? Let's have more nurses run for state legislative offices, for our House of Representatives, for the U.S. Senate," ONS member Barbara Damron, PhD, LHD, RN, FAAN, told Ryne Wilson, DNP, RN, OCN®, CNE, ONS member and member of the ONS 50th anniversary committee, during a conversation about the future of oncology nursing advocacy and health policy. Wilson spoke with Damron and ONS member Janice Phillips, PhD, RN, CENP, FADLN, FAAN, about how ONS has advanced advocacy and policy efforts over the past 50 years and its approaches for the future. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 229: How Advocacy Can Shape Your Nursing Career ONS Voice articles: Oncology Nurses Take to Capitol Hill to Advocate for Cancer Care Priorities Our Unified Voices Can Improve Cancer Survivorship Care With Voices Amplified by ONS, Oncology Nurses Speak Out for Patients and the Profession on Capitol Hill NOBC Partnerships Advance Nurses' Placements on Local and National Boards Nursing Leadership Has Space for You and Your Goals ONS courses: Advocacy 101: Making a Difference Board Leadership: Nurses in Governance Oncology Nursing Forum articles: Nurses on Boards: My Experience on the Moonshot Strengthening Oncology Nursing by Using Research to Inform Politics and Policy ONS Center for Advocacy and Health Policy Current ONS position statements Connie Henke Yarbro Oncology Nursing History Center Campaign for Tobacco-Free Kids Cancer Moonshot National Cancer Policy Forum National Council of State Boards of Nursing APRN Roundtable National Patient Advocate Foundation Nurses on Boards Coalition One Voice Against Cancer Patient Quality of Life Coalition Robert Wood Johnson Foundation Health Policy Fellows To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Phillips: "I think that there are so many pressing issues, but I'm going to start with any kind of threats or legislation that's poised to take away safety-net resources. It's really going to set us back because we all know that, particularly for minorities and certain other underserved populations, they have experienced poor cancer outcomes for a variety of reasons, variety of socioeconomic reasons, lack of access to quality screening resources—you name it. When you take away those safety net resources and take away resources for people who are already underserved, uninsured, or underinsured, it also jeopardizes their ability to get proper screening, get proper follow-up, have access to state of the art cancer services. I think the lack of affordability of health care is a problem that continues to challenge us, whether you on Medicaid or whether you have limited insurance." TS 10:16 Damron: "Because ONS is so grounded in science and research—we're not just a clinical organization; we're grounded in scholarship, science, research, and publication—we're able to take this vast network of strong clinicians [and combine it] with amazing scientists. … We've had some amazing scientists come out of ONS; some of the leading nurse scientists of all time were also oncology nurses. So by combining this, we're able to make a difference at the state and federal level. So the advocacy work that I've been involved in, state and federal levels, really involved working with the ONS staff involved with advocacy and those scientists and clinicians who brought that expertise." TS 18:19 Phillips: "I think expanding the work around multiculturalism in oncology will always be important. Are there any new partnerships or avenues that ONS can reach out to or explore? Maybe there are other specialty organizations or groups—and not always necessarily nursing— because as we think about the determinants of health, we think about things like health and all policies. Maybe there are other disciplines or other specialties that we need to embrace as we launch our agendas." TS 23:28 Damron: "As nurses, just our basic nursing training, we get these skills—we see a problem, we identify the problem, we assess what we're going to do about it, we do it, and then we evaluate what we did. Does that work or not? That's how you make policy. So we were all trained in this. Then what you bring on top of that are oncology nursing experience, whether it's clinical, whether it's research, whether it's teaching, practice, etc. Those continue to refine those skills that are basic to us as nurses. We have this built-in skill set, and we need to own it and understand it." TS 30:25